Twist Bioscience Corporation $TWST Shares Newly Acquired by Lido Advisors LLC

Lido Advisors LLC bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 42,240 shares of the company’s stock, valued at approximately $8,162,000. Lido Advisors LLC owned approximately 0.07% of Twist Bioscience at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in TWST. Fulcrum Asset Management LLP purchased a new stake in shares of Twist Bioscience in the third quarter valued at approximately $8,668,000. Brighton Jones LLC purchased a new position in Twist Bioscience during the third quarter worth approximately $231,000. Ethic Inc. lifted its position in Twist Bioscience by 77.9% during the third quarter. Ethic Inc. now owns 5,425 shares of the company’s stock worth $1,048,000 after buying an additional 2,376 shares in the last quarter. StoneX Group Inc. acquired a new position in Twist Bioscience during the third quarter worth $361,000. Finally, Abacus Wealth Partners LLC boosted its stake in Twist Bioscience by 4.3% during the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock worth $451,000 after buying an additional 96 shares during the last quarter.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 8,057 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the completion of the transaction, the chief financial officer directly owned 100,576 shares in the company, valued at approximately $18,996,794.88. This represents a 7.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 356,546 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the sale, the chief executive officer directly owned 620,589 shares of the company’s stock, valued at $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 495,279 shares of company stock worth $80,489,387. Company insiders own 3.08% of the company’s stock.

Analyst Upgrades and Downgrades

TWST has been the subject of several analyst reports. Robert W. Baird upped their target price on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. TD Cowen lifted their price target on Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Piper Sandler boosted their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $150.00 price objective on shares of Twist Bioscience in a report on Friday. Finally, UBS Group began coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Hold” and an average target price of $148.00.

Top Twist Bioscience Stories

Here are a few of the latest stories about TWST:

• Positive Sentiment: Fiscal fourth-quarter revenue rose 28% year over year to $126.6 million, ahead of analyst expectations. The quarterly loss of $0.32 per share was also narrower than estimates and improved from a $0.45 loss a year earlier. Article: Twist Bioscience Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: AI drug discovery generated $59.1 million in fiscal 2026, highlighting a growing business area for the company. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million was only slightly above the $549 million consensus. Reports characterized the outlook as insufficient to satisfy investors, helping explain why the stock fell despite the quarterly beats. Article: Twist Bio Slips Despite Q4 Beat After Underwhelming FY27 Outlook

Twist Bioscience Trading Down 6.8%

TWST opened at $114.22 on Friday. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71. The stock has a market capitalization of $7.16 billion, a PE ratio of -51.45 and a beta of 2.25. The business’s 50 day moving average price is $150.57 and its 200 day moving average price is $92.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $126.64 million during the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. Twist Bioscience’s revenue was up 26.7% compared to the same quarter last year. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.11 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.